Official UK procurement notice
Purchase of DPYD (dihydropyrimidine dehydrogenase) testing kits
Authority: NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) (Central government)
What is being bought
Published requirement descriptionAll Wales Genomics Laboratory (AWMGL) has been providing testing for DPYD (dihydropyrimidine dehydrogenase) deficiency since July 2020. Germline variants in the DPYD gene can confer an increased risk of severe or fatal toxicity for cancer patients being treated with common fluoropyrimidine based chemotherapies, 5-fluoruracil and/or capecitabine. Therefore results allow clinicians to assess if the treatment is suitable for the patient.
Due to considerable increase in the demand for the test the AWMGL intends to award a two year contract (for a period of 12 months with the option to extend for a further 12 months) to ensure continuity of service to the patients of NHS Wales.
CPV: Laboratory reagents
The lotProcurement structure
single lot · no lot value publishedLot #1
Procedure terms & legal framework
From the official record · publisher note attached- Procedure method
- Award procedure without prior publication of a call for competition
- Legal basis
- CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
- Procurement category
- Goods
- Notice status
- Awarded without competition
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Stand-alone contract (no framework)
- Competition type
- Direct award (no call for competition)
- GPA / WTO covered
- Yes (GPA)
- Recurring procurement
- Unspecified in notice
- First published
- 16 Jun 2021, 14:54 BST
- Last source update
- 16 Jun 2021, 14:54 BST
- Authority reference
CAV-STA (2021/2022) 9- FTS notice number
2021/S 000-013632- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-02bcb3Find a Tender
- Why no open competition
- The procurement falls outside the scope of application of the directive
- Published justification
All Wales Genomics Laboratory (AWMGL) has been providing testing for DPYD (dihydropyrimidine dehydrogenase) deficiency since July 2020. Germline variants in the DPYD gene can confer an increased risk of severe or fatal toxicity for cancer patients being treated with common fluoropyrimidine based chemotherapies, 5-fluoruracil and/or capecitabine. Therefore results allow clinicians to assess if the treatment is suitable for the patient.
The Elucigene DPYD assay provided by Yourgene Health UK Limited is deemed the only technology suitable for meeting the lab requirements for the following reasons;
The test has already been validated in the lab and is confirmed as being suitable for use. A change in technology or provider would require a considerable validation process which would have considerable cost and time implications to the lab and be extremely detrimental to patient care.
The technology used for the test is also used for other services provided by the AWMGL. This further provides evidence that the technology is already suitable for use and also allows streamlining of in house testing.
The equipment needed for the test is already in place and maintained. Change in technology may incur considerable extra costs from requirement to purchase and maintain new equipment.
Elucigene DPYD assay is IVD marked; thereby future-proofing the test for any future requirements for the lab to use IVD approved technologies for this test.
Test was cost assessed by the department at the point of validation and has been deemed the most cost effective method of testing (taking into consideration all the points above)
- Review procedure
The Authority will allow a minimum 10 calendar day standstill period between notifying the award decision and awarding the contract. Should additional information be required from the addressee in section 1.1 Ryan James ([email protected]).
The Contracting Authority will enter into this Contract following a minimum 10 day calendar day standstill period starting on the day after this notice is published on Find a Tender. If legal proceedings are commenced in relation to the contract award, it will be necessary to suspend the award of the contract pending further order of the Court, or the authority may voluntarily decide (at its discretion) to suspend the award of contract whilst any outstanding queries are dealt with. We will not be liable for any costs or losses incurred by you as a result of any suspension of the contract award or as a result of any other action made necessary by any challenge.
Publisher note: NOTE: To register your interest in this notice and obtain any additional information please visit the Sell2Wales Web Site at https://www.sell2wales.gov.wales/Search/Search_Switch.aspx?ID=111498. (WA Ref:111498)
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast| Awarded to | Value | Date | Status |
|---|---|---|---|
| Yourgene Health | £232,200 † | — | Awarded |
Contracts
Contract 013632-2021-CAV-STA (2021/2022) 9-1 · Yourgene Health
- Signed
- 1 Jun 2021
- Value
- £232,200
- Status
- active
Contracting authority & participating public bodies
Dispute resolution & review bodies
- High CourtReview body
Bidders & participating suppliers
1 commercial party on the notice- Yourgene HealthAwarded supplier
Official documents & specifications
Official links; attachments are not copiedNo document links were published on the notice.